B-type natriuretic peptide over N-terminal pro-brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke.
BNP
NT-proBNP
atrial fibrillation
biomarkers
cryptogenic stroke
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
20
07
2020
accepted:
06
10
2020
pubmed:
13
10
2020
medline:
13
8
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are well-known surrogates of atrial fibrillation (AF) detection but studies usually present data on either BNP or NT-proBNP. The aim was to determine and directly compare the validity of the two biomarkers as a tool to predict AF and guide prolonged cardiac monitoring in cryptogenic stroke patients. Non-lacunar acute ischaemic stroke (<72 h) patients over 55 years of age with cryptogenic stroke after standard evaluation were included in the Crypto-AF study and blood was collected. BNP and NT-proBNP levels were determined by automated immunoassays. AF was assessed by 28 days' monitoring. Highest (optimizing specificity) and lowest (optimizing sensitivity) quartiles were used as biomarker cut-offs to build predictive models adjusted by sex and age. The integrated discrimination improvement index (IDI) and DeLong test were used to compare the performance of the two biomarkers. From 320 patients evaluated, 218 were included in the analysis. AF was detected in 50 patients (22.9%). NT-proBNP (P < 0.001) and BNP (P < 0.001) levels were higher in subjects with AF and their levels correlated (r = 0.495, P < 0.001). BNP showed an increased area under the curve (0.720 vs. 0.669; P = 0.0218) and a better predictive capacity (IDI = 3.63%, 95% confidence interval 1.36%-5.91%) compared to NT-proBNP. BNP performed better than NT-proBNP in a specific model (IDI = 3.7%, 95% confidence interval 0.87%-6.5%), whilst both biomarkers performed similarly in the case of a sensitive model. Both BNP and NT-proBNP were increased in cryptogenic stroke patients with AF detection. Interestingly, BNP outperforms NT-proBNP, especially in terms of specificity.
Sections du résumé
BACKGROUND AND PURPOSE
B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are well-known surrogates of atrial fibrillation (AF) detection but studies usually present data on either BNP or NT-proBNP. The aim was to determine and directly compare the validity of the two biomarkers as a tool to predict AF and guide prolonged cardiac monitoring in cryptogenic stroke patients.
METHODS
Non-lacunar acute ischaemic stroke (<72 h) patients over 55 years of age with cryptogenic stroke after standard evaluation were included in the Crypto-AF study and blood was collected. BNP and NT-proBNP levels were determined by automated immunoassays. AF was assessed by 28 days' monitoring. Highest (optimizing specificity) and lowest (optimizing sensitivity) quartiles were used as biomarker cut-offs to build predictive models adjusted by sex and age. The integrated discrimination improvement index (IDI) and DeLong test were used to compare the performance of the two biomarkers.
RESULTS
From 320 patients evaluated, 218 were included in the analysis. AF was detected in 50 patients (22.9%). NT-proBNP (P < 0.001) and BNP (P < 0.001) levels were higher in subjects with AF and their levels correlated (r = 0.495, P < 0.001). BNP showed an increased area under the curve (0.720 vs. 0.669; P = 0.0218) and a better predictive capacity (IDI = 3.63%, 95% confidence interval 1.36%-5.91%) compared to NT-proBNP. BNP performed better than NT-proBNP in a specific model (IDI = 3.7%, 95% confidence interval 0.87%-6.5%), whilst both biomarkers performed similarly in the case of a sensitive model.
CONCLUSIONS
Both BNP and NT-proBNP were increased in cryptogenic stroke patients with AF detection. Interestingly, BNP outperforms NT-proBNP, especially in terms of specificity.
Substances chimiques
Biomarkers
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
540-547Informations de copyright
© 2020 European Academy of Neurology.
Références
Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467-2477.
Sanna T, Diener H-C, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478-2486.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
McMahon NE, Bangee M, Benedetto V, et al. Etiologic workup in cases of cryptogenic stroke: a systematic review of international clinical practice guidelines. Stroke 2020; 51: 1419-1427.
Tsivgoulis G, Katsanos AH, Mac Grory B, et al. Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients with cryptogenic cerebral ischemia. Stroke 2019; 50: 2175-2180.
Schnabel RB, Haeusler KG, Healey JS, et al. Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN International Collaboration. Circulation 2019; 140: 1834-1850.
Llombart V, Antolin-Fontes A, Bustamante A, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis. Stroke 2015; 46: 1187-1195.
Pagola J, Juega J, Francisco-Pascual J, et al. Yield of atrial fibrillation detection with textile wearable Holter from the acute phase of stroke: pilot study of Crypto-AF registry. Int J Cardiol 2018; 251: 45-50.
Pagola J, Juega J, Francisco-Pascual J, et al. Large vessel occlusion is independently associated with atrial fibrillation detection. Eur J Neurol 2020; 27: 1618-1624.
Wasser K, Weber-Krüger M, Gröschel S, et al. Brain natriuretic peptide and discovery of atrial fibrillation after stroke: a subanalysis of the find-AFRANDOMISED Trial. Stroke 2020; 51: 395-401.
Fonseca AC, Brito D, Pinho e Melo T, et al. N-terminal pro-brain natriuretic peptide shows diagnostic accuracy for detecting atrial fibrillation in cryptogenic stroke patients. Int J Stroke 2014; 9: 419-425.
Rubio Campal JM, García Torres MA, Sánchez Borque P, et al. Detecting atrial fibrillation in patients with an embolic stroke of undetermined source (from the DAF-ESUS registry). Am J Cardiol 2020; 125: 409-414.
Eysenck W, Freemantle N, Sulke N. A randomized trial evaluating the accuracy of AF detection by four external ambulatory ECG monitors compared to permanent pacemaker AF detection. J Interv Card Electrophysiol 2020; 57: 361-369.
Wachter R, Lahno R, Haase B, et al. Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia-the Find-AF study. PLoS One 2012; 7: 1-7.
Otaki Y, Watanabe T, Sato N, et al. Direct comparison of prognostic ability of cardiac biomarkers for cardiogenic stroke and clinical outcome in patients with stroke. Heart Vessels 2019; 34: 1178-1186.
Bai J, Sun H, Xie L, Zhu Y, Feng Y. Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis. Int J Neurosci 2018; 128: 1100-1108.
Yang HL, Lin YP, Long Y, Ma QL, Zhou C. Predicting cardioembolic stroke with the B-type natriuretic peptide test: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2014; 23: 1882-1889.
Kamel H, Longstreth WT, Tirschwell DL, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke 2019; 14: 207-214.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
Haeusler KG, Gröschel K, Köhrmann M, et al. Expert opinion paper on atrial fibrillation detection after ischemic stroke. Clin Res Cardiol 2018; 107: 871-880.
Buchner S, Jungbauer C, Birner C, Debl K, Riegger GA, Luchner A. Comparison of the cardiac markers B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide. Biomark Med 2009; 3: 465-481.
Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
Fonseca AC, Matias JS, e Melo TP, et al. Time course of NT-proBNP levels after acute ischemic stroke. Acta Neurol Scand 2013; 128: 235-240.
Nakagawa K, Yamaguchi T, Seida M, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005; 19: 157-164.
Brosnan MJ, Clark JS, Jeffs B, et al. Genes encoding atrial and brain natriuretic peptides as candidates for sensitivity to brain ischemia in stroke-prone hypertensive rats. Hypertension 1999; 33: 290-297.
Rørth R, Jhund PS, Yilmaz MB, et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circ Hear Fail 2020; 13: 1-10.
Semenov AG, Feygina EE. Standardization of BNP and NT-ProBNP immunoassays in light of the diverse and complex nature of circulating BNP-related peptides. Adv Clin Chem 2018; 85: 1-30.
De Marchis GM, Schneider J, Weck A, et al. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke. Neurology 2018; 90: e455-e465.